<DOC>
	<DOCNO>NCT00773773</DOCNO>
	<brief_summary>This prospective , serum proteomics study men undergo prostate biopsy . The purpose determine proteomic profile use distinguish men prostate cancer biopsy men cancer biopsy .</brief_summary>
	<brief_title>Combination Serum Measurements Molecular Biomarkers Serum Protein Profiling Can Used Predict Which Patients Undergoing Prostatic Biopsy Will Diagnosed With Cancer</brief_title>
	<detailed_description />
	<criteria>Men age 18 year old Have PSA level 2 10 ng/ml May may abnormal digital rectal examination Scheduled transrectal ultrasound ( TRUS ) guide systematic prostate biopsy part routine medical care . All site ( Department Urology SUNY Downstate Medical Center , Brooklyn , Department Urology , New York Presbyterian Hospital , Weill Medical College Cornell University , Manhattan Department Urology , Kings County Hospital ) perform standardize 14 core biopsy protocol . Signed , informed consent Patient must able attend prebiopsy blood draw Any period prior/current treatment hormonal therapy ( LHRH agonist/antagonist , antiandrogen , 5alphareductase inhibitor ) Prior pelvic radiation A period le 6 month prior/current treatment alphablocker Previous diagnosis prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Biomarkers - PSA , hK2 solubilized</keyword>
	<keyword>urokinase-receptor form ( su-PAR )</keyword>
	<keyword>08-114</keyword>
</DOC>